136 related articles for article (PubMed ID: 9657198)
41. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells.
Doisneau-Sixou SF; Cestac P; Chouini S; Carroll JS; Hamilton AD; Sebti SM; Poirot M; Balaguer P; Faye JC; Sutherland RL; Favre G
Endocrinology; 2003 Mar; 144(3):989-98. PubMed ID: 12586776
[TBL] [Abstract][Full Text] [Related]
42. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines.
Schmidt F; Knobbe CB; Frank B; Wolburg H; Weller M
Oncol Rep; 2008 Apr; 19(4):1061-6. PubMed ID: 18357397
[TBL] [Abstract][Full Text] [Related]
43. The inhibitory effect of simvastatin on growth in malignant gliomas--with special reference to its local application with fibrin glue spray in vivo.
Murakami M; Goto T; Saito Y; Goto S; Kochi M; Ushio Y
Int J Oncol; 2001 Sep; 19(3):525-31. PubMed ID: 11494031
[TBL] [Abstract][Full Text] [Related]
44. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells.
Jones KD; Couldwell WT; Hinton DR; Su Y; He S; Anker L; Law RE
Biochem Biophys Res Commun; 1994 Dec; 205(3):1681-7. PubMed ID: 7811252
[TBL] [Abstract][Full Text] [Related]
45. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
[TBL] [Abstract][Full Text] [Related]
46. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
[TBL] [Abstract][Full Text] [Related]
47. FTI-277 and GGTI-289 induce apoptosis via inhibition of the Ras/ERK and Ras/mTOR pathway in head and neck carcinoma HEp-2 and HSC-3 cells.
Tateishi K; Tsubaki M; Takeda T; Yamatomo Y; Imano M; Satou T; Nishida S
J BUON; 2021; 26(2):606-612. PubMed ID: 34077012
[TBL] [Abstract][Full Text] [Related]
48. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
49. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes.
Bernhard EJ; McKenna WG; Hamilton AD; Sebti SM; Qian Y; Wu JM; Muschel RJ
Cancer Res; 1998 Apr; 58(8):1754-61. PubMed ID: 9563495
[TBL] [Abstract][Full Text] [Related]
50. The role of geranylgeranylated proteins in human mesangial cell proliferation.
Khwaja A; Sharpe CC; Noor M; Hendry BM
Kidney Int; 2006 Oct; 70(7):1296-304. PubMed ID: 16929252
[TBL] [Abstract][Full Text] [Related]
51. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.
Pollack IF; Kawecki S; Lazo JS
J Neurosurg; 1996 Jun; 84(6):1024-32. PubMed ID: 8847567
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells.
Di Paolo A; Danesi R; Caputo S; Macchia M; Lastella M; Boggi U; Mosca F; Marchetti A; Del Tacca M
Br J Cancer; 2001 Jun; 84(11):1535-43. PubMed ID: 11384105
[TBL] [Abstract][Full Text] [Related]
53. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
54. [Correlation between inhibitory effect of Manumycin on human hepatoma cancer cell HepG2 and Ras signal transduction pathway].
Zhou JM; Pan QC; Yang XP; Liu ZC; Liao DF; Fu LW; Liang YJ
Ai Zheng; 2002 Apr; 21(4):364-8. PubMed ID: 12452012
[TBL] [Abstract][Full Text] [Related]
55. Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins.
Macchia M; Jannitti N; Gervasi G; Danesi R
J Med Chem; 1996 Mar; 39(7):1352-6. PubMed ID: 8691464
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells.
Bouterfa HL; Sattelmeyer V; Czub S; Vordermark D; Roosen K; Tonn JC
Anticancer Res; 2000; 20(4):2761-71. PubMed ID: 10953355
[TBL] [Abstract][Full Text] [Related]
57. Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor.
Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
J Neurosurg; 2003 Jan; 98(1):154-61. PubMed ID: 12546364
[TBL] [Abstract][Full Text] [Related]
58. Thromboxane synthase inhibitors induce apoptosis in migration-arrested glioma cells.
Yoshizato K; Zapf S; Westphal M; Berens ME; Giese A
Neurosurgery; 2002 Feb; 50(2):343-54. PubMed ID: 11844270
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of glucose- and calcium-induced insulin secretion from betaTC3 cells by novel inhibitors of protein isoprenylation.
Amin R; Chen HQ; Tannous M; Gibbs R; Kowluru A
J Pharmacol Exp Ther; 2002 Oct; 303(1):82-8. PubMed ID: 12235236
[TBL] [Abstract][Full Text] [Related]
60. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
